New developments in addiction treatment

Journal of Clinical Psychiatry

Volumn 67, Issue 11, 2006, Pages 1801-1812

  O'Brien, Charles P ^a   Koob, George F ^b   Mee Lee, David ^c   Rosenthal, Richard N ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c American Society of Addiction Medicine   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; BUPRENORPHINE; DISULFIRAM; METHADONE; NALTREXONE;

ALCOHOLISM; ANXIETY DISORDER; CLINICAL FEATURE; CLINICAL PRACTICE; CONFERENCE PAPER; DRUG DEPENDENCE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DYSPNEA; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; MONOTHERAPY; NEUROBIOLOGY; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

EID: 33845676677     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n1119     Document Type: Conference Paper

References (84)

1. Koob GF. Alcoholism: allostasis and beyond. Alcohol Clin Exp Res 2003;27:232-243
2. O'Malley SS, Krishnan-Sarin S, Farren C, et al. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalmo-pituitary-adrenocortical axis. Psychopharmacology (Berl) 2002;160:19-29
3. Spanagel R. The role of the glutamatergic system in alcohol addiction. Fortschr Neurol Psychiatr 2003;71(suppl 1):S33-S35
4. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997; 278:52-58
5. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci 2005;8:1445-1449
6. Funk C, Zorrilla EP, Lee MJ, et al. Corticotropin-releasing factor 1 agonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biol Psychiatry 2006;Epub ahead of print
7. Valdez GR, Roberts AJ, Chan K, et al. Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor. Alcohol Clin Exp Res 2002;26:1494-1501
8. Valdez GR, Sabino V, Koob GF. Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin-releasing factor-2 receptor activation. Alcohol Clin Exp Res 2004;28:865-872
9. Valdez GR, Zorilla EP, Roberts AJ, et al. Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. Alcohol 2003;29:55-60
10. Roberts AJ, Heyser CJ, Cole M, et al. Excessive ethanol drinking following a history of dependence: animal model of allostasis. Neuropsychopharmacology 2000;22:581-594
11. Heyser CJ, Schulteis G, Durbin P, et al. Chronic acamprosate eliminates deprivation effect while having limited effects on baseline responding for ethanol rats. Neuropsychopharmacology 1998;18:125-133
12. Dahchour A, De Witte P, Bolo N, et al. Central effects of acamprosate, pt 1: acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res 1998;82:107-114
13. Liu X, Weiss F. Additive effect of stress and drug cues on reinstatement of ethanol-seeking: exacerbation by history of dependence and role of concurrent activation of corticotrophin-releasing factor and opioid mechanisms. J Neurosci 2002;22:7856-7861
14. Pickering C, Liljequist S. Cue-induced behavioural activation: a novel model of alcohol craving? Psychopharmacology (Berl) 2003;168:307-313
15. Erb S, Salmaso N, Rodaros D, et al. A role for the CRF-containing pathway from central nucleus of the amygdala to bed nucleus of the stria terminalis in the stress-induced reinstatement of cocaine seeking in rats. Psychopharmacology (Berl) 2001;158:360-365
16. Williams SH. Medications for treating alcohol dependence. Am Fam Physician 2005;72:1775-1780
17. Jung YC, Namkoong K. Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention. Yonsei Med J 2006;47:167-178
18. Garbutt JC, West SL, Carey TS, et al. Pharmacologic treatment of alcohol dependence: a review of the evidence. JAMA 1999;281:1318-1325
19. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1994;51:335-336
20. Stromberg MF, Mackler SA, Volpicelli JR, et al. Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption. Alcohol 2001;23:109-116
21. Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci 1998; 18:10663-10671
22. Bart G, Kreek MJ, On J, et al. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 2005;30:417-422
23. Wand GS, McCaul M, Yang X, et al. The muopioid receptor gene polymorphism (Al 18G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 2002;26:106-114
24. Gianoulakis C, Krishnan B, Thavundavil J. Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism. Arch Gen Psychiatry 1996; 53:250-257
25. Gianoulakis C. Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies. Alcohol Alcohol 1996;31(suppl 1):33-42
26. Davidson D, Hutchison K, Dagon C, et al. Assessing the stimulant effects of alcohol in humans. Pharmacol Biochem Behav 2002; 72:151-156
27. Dunbar JL, Turncliff RZ, Donq Q, et al. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res 2006;30:480-490
28. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005;293:1617-1625
29. Kranzler HR, Wesson DR, Billot L, et al. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 2004;28:1051-1059
30. Vivitrol [package insert]. Frazer, PA: Cephalon Pharmaceuticals; 2005. Available at http://www.vivitrol.com/pdf_docs/prescribing_info.pdf. Accessed Sept 28, 2006
31. al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate, pt 2: ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 1998;22:810-814
32. Chick J, Lehert P, Landron F, et al. Does acamprosate improve reduction of drinking as well as aiding abstinence? J Psychopharrnacol 2003;17:397-402
33. Soyka M, Preuss U, Scheutz C. Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism: results from a non-blind, multicentre study. Drugs R D 2002;3:1-12
34. Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996;53:673-680
35. Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol 2001;36:413-418
36. Cole JC, Littleton JM, Little HJ. Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze. Psychopharmacology (Berl) 2000;147:403-111
37. Pelc I, Verbank P, Le Bon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: a 90-day placebo-controlled dose-finding study. Br J Psychiatry 1997;171:73-77
38. Berton F, Francesconi WG, Madamba SG, et al. Acamprosate enhances N-methyl-d-aspartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons. Alcohol Clin Exp Res 1998;22:183-191
39. Mason BJ, Goodman AM, Dixon RM, et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002;27:596-606
40. Johnson BA, O'Malley SS, Ciraulo DA, et al. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J Clin Psychopharmacol 2003;23:281-293
41. Boothby LA, Doering PL. Acamprosate for the treatment of alcohol dependence. Clin Ther 2005;27:695-714
42. Mason BJ. Rationale for combining acamprosate and naltrexone for treating alcohol dependence. J Stud Alcohol Suppl 2005;15:148-156
43. Kiefer F, Wiedmann K. Combined therapy: what does acamprosate and naltrexone combination tell us? Alcohol Alcohol 2004;39:542-547
44. Feeney GF, Connor JP, Young RM, et al. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centre's experience with pharmacotherapy. Alcohol Alcohol 2006;41:321-327.
45. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006;295:2003-2017
46. Oslin DW. Treatment of late-life depression complicated by alcohol dependence. Am J Geriatr Psychiatry 2005;13:491-500
47. Mason BJ, Kocsis JH, Ritvo EC, et al. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996;275:761-767
48. Mee-Lee D, Shulman GD, Fishman M, et al. eds. Patient Placement Criteria for the Treatment of Substance-Related Disorders. 2nd Revised ed. Chevy Chase, Md: American Society of Addiction Medicine; 2001
49. Hoffmann NG, Halikas JA, Mee-Lee D, et al. Patient Placement Criteria for the Treatment of Psychoactive Substance Use Disorders. Washington, DC: American Society of Addiction Medicine; 1991
50. Hoffmann NG, Halikas JA, Mee-Lee D. The Cleveland Admission, Discharge, and Transfer Criteria: Model for Chemical Dependency Treatment Programs. Cleveland, Ohio: Northern Ohio Chemical Dependency Treatment Directors Association; 1987
51. Weedman RD. Admission, Continued Stay and Discharge Criteria for Adult and Adolescent Alcoholism and Drug Dependence Treatment Services. Irvine, Calif: National Association of Addiction Treatment Providers; 1987
52. American Society of Addiction Medicine. Patient Placement Criteria for the Treatment of Substance-Related Disorders (ASAM PPC-2). Chevy Chase, Md: American Society of Addiction Medicine; 1996
53. Sharon E, Krebs C, Turner W, et al. Predictive validity of the ASAM Patient Placement Criteria for hospital utilization. J Addict Dis 2003;22(suppl 1):79-93
54. Mee-Lee D. Persons with addictive disorders, system failures, and managed care. In: Ross EC, ed. Managed Behavioral Health Care Handbook. Gaithersburg, MD: Aspen Publisher; 2001:225-265
55. Miller SD, Mee-Lee D, Plum W, et al. Making treatment count: client-directed, outcome informed clinical work with problem drinkers. In: Lebow J, ed. Handbook of Clinical Family Therapy. New York, NY: Wiley; 2005:281-308
56. Mee-Lee D. Use of Patient Placement Criteria in the selection of treatment. In: Graham AW, Schultz TK, eds. Principles of Addiction Medicine. 2nd ed. Chevy Chase, Md: American Society of Addiction; 1998:363-370
57. Mee-Lee D, Shulman GD. The ASAM Patient Placement Criteria and matching patients to treatment. In: Graham AW, Schultz TK, Mayo-Smith MF, et al, eds. Principles of Addiction Medicine. 3rd ed. Chevy Chase, Md: American Society of Addiction Medicine; 2003
58. Gastfriend DR, Mee-Lee D. The ASAM Patient Placement Criteria: context, concepts, and continuing development. J Addict Dis 2003;22(suppl 1):1-8
59. Rosenthal RN, Reimer J. Die rolle von standards in der suchtenbehandling in den vereiningten Staaten von Amerika. Suchttherpie 2002;3(suppl 2):S117-S119
60. Lohr KN, Carey TS. Assessing "best evidence": issues in grading the quality of studies for systematic reviews. Jt Comm J Qual Improv 1999;25:470-479
61. Rosenthal RN. Concepts of evidence-based practice. In: Roberts AR, Yeager KR, eds. Evidence-Based Practice Manual: Research and Outcome Measures in Health and Human Services. New York, NY: Oxford University Press; 2004:20-29
62. O'Brien CP. Overview: the treatment of drug dependence. Addiction 1994;89:1565-1569
63. Ries RK, Comtois KA. Illness severity and treatment services for dually diagnosed severely mentally ill outpatients. Schizophr Bull 1997;23:239-246
64. Rosenthal RN, Westreich L. Treatment of persons with dual diagnosis of substance use disorder and other psychological problems. In: McGrady BS, Epstein EE, eds. Addictions: A Comprehensive Guidebook. New York, NY: Oxford University Press; 1999:439-476
65. Buckley PF. Prevalence and consequences of dual diagnosis. J Clin Psychiatry 2006;67 (suppl 7):5-9
66. Narrow WE, Regier DA, Rae DS, et al. Use of services by persons with mental and addictive disorders: findings from the National Institute of Mental Health Epidemiologic Catchment Area Program. Arch Gen Psychiatry 1993;50:95-107
67. Managing alcoholism treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol 1997; 58:7-29
68. Waltz J, Addis ME, Koerner K, et al. Testing the integrity of a psychotherapy protocol: assessment of adherence and competence. J Consult Clin Psychol 1993;61:620-630
69. McLellan AT, Carise D, Kleber HD. Can the national addiction treatment infrastructure support the public's demands for quality care? J Subst Abuse Treat 2003;25:117-121
70. D'Aunno T, Vaughn TE. Variations in methadone treatment practices: results from a national study. JAMA 1992;267:253-258
71. Frank RG, McGuire TG, Regier DA, et al. Paying for mental health and substance abuse care. Health Aff 1994;13:337-342
72. Kessler RC, Nelson CB, McGonagle KA, et al. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 1996;66:17-31
73. Mark TL, Woody GE, Juday T, et al. The economic costs of heroin addiction in the United States. Drug Alcohol Depend 2001;61:195-206
74. National Institute on Drug Abuse. Principles of drug addiction treatment: a research based guide. 2005. Available at: http://www.nida.nih.gov/podat/ PODAT6.html#FAQ11. Accessed Aug 2, 2006
75. Gerstein DR, Harwood H, Fountain Del al. Evaluating recovery services: the California Drug and Alcohol Treatment Assessment (CALDATA). 2004; Available at http://www.adp.state.ca.us. Accessed Aug 30, 2006
76. Fleming MF, Mundt MP, French MT, et al. Brief physician advice for problem drinkers: long-term efficacy and benefit-cost analysis. Alcohol Clin Exp Res 2002;26:36-43
77. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004;61:807-816
78. Gossop M. The Treatment Mapping Survey: a descriptive study of drug and alcohol treatment responses in 23 countries. Drug Alcohol Depend 1995;39:7-14
79. Warner LA, Kessler RC, Hughes M, et al. Prevalence and correlates of drug use and dependence in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1995;52:219-229
80. United States Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. National Survey of Substance Abuse Treatment Services. Arlington, Va: Syntectics for Management Decisions, Inc.; 2004
81. Ananth J, Vandewater S, Kamal M, et al. Missed diagnosis of substance abuse in psychiatric patients. Hosp Community Psychiatry 1989;40:297-299
82. Rosenthal RN, Hellerstein DJ, Miner CR, et al. Integrated services for treatment of schizophrenia substance abusers: demographics, symptoms, and substance abuse patterns. Psychiatr Q 1992;63:3-26
83. Condelli WS, Dunteman GH. Exposure to methadone programs and heroin use. Am J Drug Alcohol Abuse 1993;19:65-78
84. Carroll KM, Onken LS. Behavioral therapies for drug abuse. Am J Psychiatry 2005:162:1452-1460